Loading ...

The National Institute for Health and Care Excellence (NICE) has recommended mirvetuximab soravtansine (Elahere, AbbVie) for treating folate receptor alpha-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have received one to three prior lines of systemic treatment. 

The recommendation, published in final draft guidance, addresses a critical treatment gap for patients whose disease progresses within 6 months after platinum-based chemotherapy.

Quality of Life and Treatment Burden

Platinum resistance, defined as disease progression within 6 months of completing platinum-based chemotherapy, presents a major clinical bottleneck. Current standard therapies such as weekly paclitaxel or pegylated liposomal doxorubicin offer limited efficacy and carry a heavy toxicity burden, including debilitating peripheral neuropathy, extreme fatigue, alopecia, ascites, and gastrointestinal distress.

Mirvetuximab soravtansine works by directly targeting folate receptor alpha, a cell-surface receptor expressed on tumour cells in eligible patients, delivering its cytotoxic payload directly to the tumour cells and limiting exposure of healthy tissue.

“For women living with platinum-resistant ovarian cancer, the impact of repeated chemotherapy cycles goes far beyond the clinic,” said Lucy Common, clinical nursing advisor at NICE. “Mirvetuximab soravtansine offers not just longer survival, but a meaningfully different treatment experience, with fewer hospital visits and a side effect profile that allows women to maintain more of their normal life.”

Patient surveys and clinical expert testimony compiled during the NICE evaluation described chemotherapy as disrupting work, social life, and daily activities, with many patients relying heavily on family or carers. For patients who had received mirvetuximab soravtansine, most reported fewer side effects and a substantially improved quality of life.

Clinical Evidence and Patient Outcomes

The recommendation was based primarily on data from the phase 3 MIRASOL trial, which evaluated 453 patients with folate receptor alpha-positive, platinum-resistant ovarian cancer. Participants were randomized to receive either mirvetuximab soravtansine or an investigator's choice of standard chemotherapy (including paclitaxel, pegylated liposomal doxorubicin, or topotecan).

The trial demonstrated significant improvements in both progression-free survival (hazard ratio [HR], 0.63; 95% CI, 0.51-0.79), representing a 37% reduction in risk for disease progression or death, and overall survival (HR, 0.68; 95% CI, 0.54-0.84), representing a 32% reduction in risk for death, compared with standard chemotherapy.

Women receiving mirvetuximab soravtansine lived an average of 16.9 months compared with 13 months with chemotherapy. Cancer progression was also delayed, with women on mirvetuximab soravtansine having an average of 5.6 months before their disease worsened, compared with 4 months with chemotherapy.

Dosing, Cost, and Implementation

Mirvetuximab soravtansine is given as an intravenous infusion by a doctor or nurse with experience in cancer medicines. The dose is calculated based on the patient's body weight.

The drug will be available at a list price of £4950 per 100-mg vial, though AbbVie has established a commercial arrangement providing a confidential discount to the NHS. 

Around 270 patients are expected to be eligible in the first year, rising to approximately 420 by year 3 as access to the diagnostic test needed to confirm eligibility becomes more widely available.

The antibody-drug conjugate will be available to eligible patients in England immediately through interim Cancer Drugs Fund access and will switch to routine commissioning 90 days after NICE publishes final guidance.